Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta
- PMID: 11970931
- PMCID: PMC1751119
- DOI: 10.1136/adc.86.5.356
Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta
Abstract
Aim: To find an effective symptomatic treatment for osteogenesis imperfecta (OI).
Methods: In a prospective observational study disodium pamidronate (APD) was given as monthly intravenous infusions to 28 children and adolescents (aged 0.6-18 years) with severe OI or a milder form of the disease, but with spinal compression fractures.
Results: During treatment for 2-9 years, dual energy x ray absorptiometry measurements of the total body and of the lumbar spine showed a gradual increase in bone density. All bone metabolism variables in serum (alkaline phosphatase, osteocalcin, procollagen 1 C-terminal peptide, collagen 1 teleopeptide) and urine (deoxypyridinoline) indicated that there was a decrease in bone turnover. All patients experienced beneficial effects and the younger patients reported a major improvement in wellbeing, pain, and mobility without significant side effects. Vertebral remodelling was also seen.
Conclusions: APD seems to be an efficient symptomatic treatment for children and adolescents with OI.
Figures
Comment in
-
Osteogenesis imperfecta and intravenous pamidronate.Arch Dis Child. 2002 Dec;87(6):562-3. doi: 10.1136/adc.87.6.562-a. Arch Dis Child. 2002. PMID: 12456578 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical